Phuturdex › Diseases › Neuroendocrine carcinoma
Drugs in development · updated 30 October 2026
Neuroendocrine carcinoma: drugs in development
As of 30 October 2026 there are 46 active clinical trials (recruiting or ongoing, phases I–III) on 55 drugs for neuroendocrine carcinoma. 29 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| ZG006 | III | 5 | NCT07595913 |
| ZG005 | III | 2 | NCT07833839 |
| Ifinatamab Deruxtecan | I–II | 2 | NCT06330064 |
| SurufatinibSulfatinib, Sevsury® | I–II | 2 | NCT05747729 |
| 177Lu-Octreotate | II | 1 | NCT02754297 |
| CRN09682 | I–II | 1 | NCT07129252 |
| CTX-471 | II | 1 | NCT07684170 |
| CVM-1118 | II | 1 | NCT03600233 |
| DomvanalimabAB154 | II | 1 | NCT07337447 |
| Gocatamig | I–II | 1 | NCT04471727 |
| IDE161 | I–II | 1 | NCT07174583 |
| IDE849 | I–II | 1 | NCT07174583 |
| Ivocizumab | II | 1 | NCT06683846 |
| IvonescimabAK112 | II | 1 | NCT07712094 |
| MT-4561 | I–II | 1 | NCT06943521 |
| ObrixtamigBI 764532 | II | 1 | NCT07561645 |
| Peluntamig | I–II | 1 | NCT05652686 |
| SerplulimabHLX10, Hetronifly® | I–II | 1 | NCT05747729 |
| SintilimabSinitilimab, Sindilimab | II | 1 | NCT07156019 |
| ZimberelimabAB122, GLS-010 | II | 1 | NCT07337447 |
| ABBV-706 | I | 1 | NCT05599984 |
| ADCT-701 | I | 1 | NCT06041516 |
| BL-M14D1 | I | 1 | NCT07080242 |
| BudigalimabABBV-181 | I | 1 | NCT05599984 |
| CID-078 | I | 1 | NCT06577987 |
| Elimusertib | I | 1 | NCT04514497 |
| HS-20108 | I | 1 | NCT06936735 |
| ML261 | I | 1 | NCT07488923 |
| TLN-499 | I | 1 | NCT07713732 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| CisplatinCis Platinum, Cisplatine | III | 6 | NCT07833839 |
| EtoposideAvopef®, Etopophos Preservative Free® | III | 4 | NCT07833839 |
| IrinotecanOnivyde, CPT-11 | III | 4 | NCT07595913 |
| TarlatamabImdelltra®, Imdylltra® | III | 3 | NCT06937905 |
| Fluorouracil5-Fluorouracil, Adrucil | III | 1 | NCT07595913 |
| AtezolizumabTecentriq, MPDL3280A | I–II | 5 | NCT05652686 |
| CarboplatinCarboplatine, Paraplatin | I–II | 4 | NCT05652686 |
| NivolumabOpdivo, ONO-4538 | I–II | 4 | NCT03647163 |
| IpilimumabYERVOY, ipililumab IV | I–II | 3 | NCT03647163 |
| DostarlimabTSR-042, Jemperli® | II | 2 | NCT04701307 |
| TemozolomideTemodal, Temodar | II | 2 | NCT02595424 |
| TopotecanHycamtin®, Topotecan Hospira® | I–II | 2 | NCT05652686 |
| BelinostatBeleodaq® | II | 1 | NCT06406465 |
| Bevacizumabavastin, MVASI | II | 1 | NCT03074513 |
| Cabozantinib S-malateCabometyx®, Cometriq® | II | 1 | NCT04079712 |
Sorted by most advanced phase and number of active trials. Showing 15 of 26 drugs.
All 55 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Merkel cell carcinoma 48 drugs
- Melanoma 352 drugs
- Non-small-cell lung carcinoma 726 drugs
- Medullary carcinoma 13 drugs
- Renal cell carcinoma 228 drugs
- Metastasis 493 drugs
- Basal-cell carcinoma of the skin 28 drugs
- Skin neoplasm 50 drugs
- Stomach neoplasm 340 drugs
- Uterine cervix neoplasm 224 drugs
- Head and neck squamous cell carcinoma 321 drugs
- Transitional cell carcinoma 146 drugs
Broader categories
- Glandular and epithelial neoplasm 12 drugs
- Nerve tissue neoplasm 4 drugs
- Adenocarcinoma 111 drugs
- Neuroectodermal tumor 3 drugs
- Germ cell and embryonal neoplasms 35 drugs
- Carcinoma 137 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D018278 “Carcinoma, Neuroendocrine”.